Actinium Pharmaceuticals Inc ATNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATNM is a good fit for your portfolio.
News
-
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
-
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
-
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
-
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
-
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Trading Information
- Previous Close Price
- $7.38
- Day Range
- $7.31–7.98
- 52-Week Range
- $4.00–9.86
- Bid/Ask
- $7.33 / $7.98
- Market Cap
- $226.35 Mil
- Volume/Avg
- 282,660 / 371,188
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2,581.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.actiniumpharma.com
Comparables
Valuation
|
Metric
|
ATNM
|
CLDX
|
MRSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.16 | 4.87 | 10.37 |
Price/Sales | 2,581.29 | 263.40 | 9.99 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATNM
|
CLDX
|
MRSN
|
|---|---|---|---|
Quick Ratio | 10.42 | 13.69 | 3.29 |
Current Ratio | 10.59 | 13.87 | 3.36 |
Interest Coverage | — | — | −44.11 |
Quick Ratio
ATNM
CLDX
MRSN
Profitability
|
Metric
|
ATNM
|
CLDX
|
MRSN
|
|---|---|---|---|
Return on Assets (Normalized) | −45.91% | −30.49% | −49.57% |
Return on Equity (Normalized) | −90.18% | −33.19% | −211.52% |
Return on Invested Capital (Normalized) | −93.20% | −32.85% | −146.81% |
Return on Assets
ATNM
CLDX
MRSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Twgjhrmbb | Xdnkq | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zzkfbmkj | Bncvspm | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qlyxtjbz | Lvzjsd | $98.1 Bil | |
MRNA
| Moderna Inc | Rwnfgpky | Fdtgq | $42.2 Bil | |
ARGX
| argenx SE ADR | Cjqxbbtxz | Hljl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Bjtlzpz | Fqfj | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Clmzkxz | Mhyvvl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ywlkqdth | Vcfqn | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wqbxpppdz | Gfnsgdl | $12.5 Bil | |
INCY
| Incyte Corp | Sbbpzgyzx | Hxlmw | $11.7 Bil |